E3 PreliminaryPreliminaryPEM unclearPeer-reviewedMachine draft
Open-label study of s-citalopram therapy of chronic fatigue syndrome and co-morbid major depressive disorder.
Amsterdam, Jay D, Shults, Justine, Rutherford, Nancy · Progress in neuro-psychopharmacology & biological psychiatry · 2008 · DOI
Quick Summary
This study tested whether an antidepressant medication called s-citalopram could help people with ME/CFS who also had depression. Sixteen patients took the medication for up to 12 weeks, and researchers measured changes in fatigue, pain, sleep, and mood using standard questionnaires. The results showed improvements in fatigue severity, several ME/CFS symptoms, and depression scores during treatment.
Why It Matters
This study addresses the challenge of treating ME/CFS patients with concurrent depression, a common clinical situation. The observed improvements in both ME/CFS symptom severity and depression suggest potential therapeutic benefit for this population, though methodological limitations require cautious interpretation.
Observed Findings
- Significant reductions in fatigue severity on the Chalder Fatigue Questionnaire (p<0.0005) and Fatigue Impact Scale (p<0.0005)
- Improvement in 5 of 8 core CFS symptoms: post-exertion malaise, headaches, unrefreshing sleep, and impaired memory/concentration
- Significant reductions in depression severity on the Hamilton Depression Rating Scale (p<0.0005) and Beck Depression Inventory (p<0.0005)
- Improvement in clinical global impression ratings for both CFS and MDD severity and change over the 12-week treatment period
Inferred Conclusions
- S-citalopram therapy may be effective in improving both CFS symptom severity and comorbid major depressive disorder in this patient population
- Antidepressant treatment targeting depression may secondarily improve certain core ME/CFS symptoms, particularly those related to sleep, pain, and cognition
- The symptom domains most responsive to treatment were post-exertion malaise, headaches, and sleep quality
Remaining Questions
- Does s-citalopram improve outcomes in ME/CFS patients without comorbid depression, or are benefits specific to the depressed subgroup?
- How do effects of s-citalopram compare to placebo in a randomized controlled trial?
- Which ME/CFS symptoms (especially post-exertion malaise) are genuinely improved versus temporarily masked by mood improvement?
What This Study Does Not Prove
This open-label, uncontrolled study cannot establish that s-citalopram caused the observed improvements—responses could reflect placebo effect, natural recovery, or regression to the mean. The small sample (n=16) and lack of randomization or control group mean findings cannot be generalized to the broader ME/CFS population. The study also does not clarify whether antidepressants are beneficial for ME/CFS patients without depression.
Tags
Symptom:Post-Exertional MalaiseCognitive DysfunctionUnrefreshing SleepPainFatigue
Method Flag:PEM Not DefinedWeak Case DefinitionNo ControlsSmall Sample
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →